<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625545</url>
  </required_header>
  <id_info>
    <org_study_id>CP00001</org_study_id>
    <nct_id>NCT02625545</nct_id>
  </id_info>
  <brief_title>Study of Median Lobe Prostatic UroLift Procedure</brief_title>
  <official_title>Study of Median Lobe Prostatic UroLift Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoTract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoTract, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of using UroLift in
      subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives: Evaluate the safety and effectiveness of the UroLift® System when used in
      symptomatic benign prostatic hyperplasia (BPH) subjects with an enlarged median lobe.

      Study Design: Prospective, multicenter, non-blinded, single arm (non-randomized) study.

      Sample Size: A total of no more than 48 subjects will be enrolled. Subject Population: Males
      age of 50 years or older diagnosed with lower urinary tract symptoms (LUTS) with enlarged
      median lobe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2016</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%.</measure>
    <time_frame>6 months</time_frame>
    <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population International Prostate Symptom Scores at Baseline and 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population International Prostate Symptom Score Percent Change From Baseline to 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Present change in Intent to Treat population International Prostate Symptom Score (IPSS) from Baseline to 12 Month Follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population Quality of Life Scores at Baseline and 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Quality of Life (QOL) score results from a disease-specific (BPH) quality of life question (bother score) scored on a scale from 0 to 6 points (delighted to terrible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population Quality of Life Score Perfect Change From Baseline to 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Quality of Life (QOL) score results from a disease-specific (BPH) quality of life question (bother score) scored on a scale from 0 to 6 points (delighted to terrible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population BPHII Scores at Baseline and 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>BPHII (Benign Prostatic Hyperplasia Impact Index) is used to assess the impact of BPH symptoms on subject health and functioning. The BPHII is a self-administered questionnaire with 4 questions about urinary problems during the past month regarding physical discomfort, worry about health, how bothersome symptoms are, and whether the symptoms are interfering with doing usual activities. Scores for each question range from 0 to 4, with higher score indicating greater impact. Maximum score is 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population BPHII Score Percent Change From Baseline to 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Present change in Intent to Treat population, Benign Prostatic Hyperplasia Impact Index (BPHII) score from Baseline to 12 Month Follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population Peak Flow Rate Scores at Baseline and 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Peak or maximum flow rate [ml/sec] was collected using uroflowmetry, a standard diagnostic used to test to assess how well the urinary tract functions. A lower number indicates a reduced flow rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population Peak Flow Rate Percent Change From Baseline to 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Peak or maximum flow rate [ml/sec] was collected using uroflowmetry, a standard diagnostic used to test to assess how well the urinary tract functions. A lower number indicates a reduced flow rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population Post Void Residual Measurement at Baseline and 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Post Residual Void (PVR) is the amount of urine left in the bladder after using the restroom. PVR is determined using ultrasound or bladder scanner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Treat Population Post Void Residual Change From Baseline to 12 Month Follow-up</measure>
    <time_frame>12 Months</time_frame>
    <description>Post Residual Void (PVR) is the amount of urine left in the bladder after using the restroom. PVR is determined using ultrasound or bladder scanner.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>UroLift System procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible,enrolled subjects will undergo a UroLift procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UroLift System procedure</intervention_name>
    <description>Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
    <arm_group_label>UroLift System procedure</arm_group_label>
    <other_name>Prostatic UroLift (PUL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enlarged median lobe (ML) contributing to obstruction of the prostate

          -  BPH

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan B. Rukstalis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <results_first_submitted>May 30, 2018</results_first_submitted>
  <results_first_submitted_qc>February 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02625545/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>UroLift System Procedure</title>
          <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Month</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (analysis population)</population>
      <group_list>
        <group group_id="B1">
          <title>UroLift Arm</title>
          <description>Subjects that undergo the UroLift System procedure.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IPSS Baseline</title>
          <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%.</title>
        <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
        <time_frame>6 months</time_frame>
        <population>Intent to treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%.</title>
          <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
          <population>Intent to treat Population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="50.8" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population International Prostate Symptom Scores at Baseline and 12 Month Follow-up</title>
        <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population International Prostate Symptom Scores at Baseline and 12 Month Follow-up</title>
          <description>The International Prostate Symptom Score (IPSS) is a standardized 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of the symptoms of the disease benign prostatic hyperplasia (BPH). The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.Those patients scoring 7 or below are generally considered mildly symptomatic, whereas 20 or above is considered severely symptomatic.</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow up visit.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IPSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month IPSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population International Prostate Symptom Score Percent Change From Baseline to 12 Month Follow-up</title>
        <description>Present change in Intent to Treat population International Prostate Symptom Score (IPSS) from Baseline to 12 Month Follow-up</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population International Prostate Symptom Score Percent Change From Baseline to 12 Month Follow-up</title>
          <description>Present change in Intent to Treat population International Prostate Symptom Score (IPSS) from Baseline to 12 Month Follow-up</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.1" lower_limit="-63.6" upper_limit="-46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population Quality of Life Scores at Baseline and 12 Month Follow-up</title>
        <description>Quality of Life (QOL) score results from a disease-specific (BPH) quality of life question (bother score) scored on a scale from 0 to 6 points (delighted to terrible).</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population Quality of Life Scores at Baseline and 12 Month Follow-up</title>
          <description>Quality of Life (QOL) score results from a disease-specific (BPH) quality of life question (bother score) scored on a scale from 0 to 6 points (delighted to terrible).</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population Quality of Life Score Perfect Change From Baseline to 12 Month Follow-up</title>
        <description>Quality of Life (QOL) score results from a disease-specific (BPH) quality of life question (bother score) scored on a scale from 0 to 6 points (delighted to terrible).</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population Quality of Life Score Perfect Change From Baseline to 12 Month Follow-up</title>
          <description>Quality of Life (QOL) score results from a disease-specific (BPH) quality of life question (bother score) scored on a scale from 0 to 6 points (delighted to terrible).</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.1" lower_limit="-69.5" upper_limit="-52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population BPHII Scores at Baseline and 12 Month Follow-up</title>
        <description>BPHII (Benign Prostatic Hyperplasia Impact Index) is used to assess the impact of BPH symptoms on subject health and functioning. The BPHII is a self-administered questionnaire with 4 questions about urinary problems during the past month regarding physical discomfort, worry about health, how bothersome symptoms are, and whether the symptoms are interfering with doing usual activities. Scores for each question range from 0 to 4, with higher score indicating greater impact. Maximum score is 16.</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population BPHII Scores at Baseline and 12 Month Follow-up</title>
          <description>BPHII (Benign Prostatic Hyperplasia Impact Index) is used to assess the impact of BPH symptoms on subject health and functioning. The BPHII is a self-administered questionnaire with 4 questions about urinary problems during the past month regarding physical discomfort, worry about health, how bothersome symptoms are, and whether the symptoms are interfering with doing usual activities. Scores for each question range from 0 to 4, with higher score indicating greater impact. Maximum score is 16.</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>BPHII score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline BPHII</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month BPHII</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population BPHII Score Percent Change From Baseline to 12 Month Follow-up</title>
        <description>Present change in Intent to Treat population, Benign Prostatic Hyperplasia Impact Index (BPHII) score from Baseline to 12 Month Follow-up</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population BPHII Score Percent Change From Baseline to 12 Month Follow-up</title>
          <description>Present change in Intent to Treat population, Benign Prostatic Hyperplasia Impact Index (BPHII) score from Baseline to 12 Month Follow-up</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.4" lower_limit="-81.9" upper_limit="-59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population Peak Flow Rate Scores at Baseline and 12 Month Follow-up</title>
        <description>Peak or maximum flow rate [ml/sec] was collected using uroflowmetry, a standard diagnostic used to test to assess how well the urinary tract functions. A lower number indicates a reduced flow rate.</description>
        <time_frame>12 Months</time_frame>
        <population>37/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit. Includes only cases where voided volume is at least 125ml.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population Peak Flow Rate Scores at Baseline and 12 Month Follow-up</title>
          <description>Peak or maximum flow rate [ml/sec] was collected using uroflowmetry, a standard diagnostic used to test to assess how well the urinary tract functions. A lower number indicates a reduced flow rate.</description>
          <population>37/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit. Includes only cases where voided volume is at least 125ml.</population>
          <units>mL/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Qmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Qmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population Peak Flow Rate Percent Change From Baseline to 12 Month Follow-up</title>
        <description>Peak or maximum flow rate [ml/sec] was collected using uroflowmetry, a standard diagnostic used to test to assess how well the urinary tract functions. A lower number indicates a reduced flow rate.</description>
        <time_frame>12 Months</time_frame>
        <population>37/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit. Includes only cases where voided volume is at least 125ml.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population Peak Flow Rate Percent Change From Baseline to 12 Month Follow-up</title>
          <description>Peak or maximum flow rate [ml/sec] was collected using uroflowmetry, a standard diagnostic used to test to assess how well the urinary tract functions. A lower number indicates a reduced flow rate.</description>
          <population>37/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit. Includes only cases where voided volume is at least 125ml.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.4" lower_limit="64.0" upper_limit="152.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population Post Void Residual Measurement at Baseline and 12 Month Follow-up</title>
        <description>Post Residual Void (PVR) is the amount of urine left in the bladder after using the restroom. PVR is determined using ultrasound or bladder scanner.</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population Post Void Residual Measurement at Baseline and 12 Month Follow-up</title>
          <description>Post Residual Void (PVR) is the amount of urine left in the bladder after using the restroom. PVR is determined using ultrasound or bladder scanner.</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline PVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.5" spread="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month PVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" spread="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Treat Population Post Void Residual Change From Baseline to 12 Month Follow-up</title>
        <description>Post Residual Void (PVR) is the amount of urine left in the bladder after using the restroom. PVR is determined using ultrasound or bladder scanner.</description>
        <time_frame>12 Months</time_frame>
        <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Treat Population Post Void Residual Change From Baseline to 12 Month Follow-up</title>
          <description>Post Residual Void (PVR) is the amount of urine left in the bladder after using the restroom. PVR is determined using ultrasound or bladder scanner.</description>
          <population>44/45, 1 Subject was retreated with additional UroLift System devices prior to the 12 month Follow-up visit.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-38.1" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Months</time_frame>
      <desc>Adverse Events reported from Index Procedure through 12 Months follow-up; No Unexpected Adverse Device Events</desc>
      <group_list>
        <group group_id="E1">
          <title>UroLift System Procedure</title>
          <description>All eligible,enrolled subjects will undergo a UroLift procedure
UroLift System procedure: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia/Heartblock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in hip</sub_title>
                <description>Right Hip Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <description>cervical spinal stenosis cord compression</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <description>blood clot in urine</description>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <description>Urinary urgency</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emily Hergenreter, Sr. Director of Clinical Affairs</name_or_title>
      <organization>NeoTract/Teleflex</organization>
      <phone>650-793-5570</phone>
      <email>Emily.Hergenreter@Teleflex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

